Podcasts

John Lieske, M.D., describes Mayo Clinic Laboratories' new test for primary membranous nephropathy. PMND1 is a diagnostic cascade that provides a cost-effective approach to detecting antigens known to cause membranous nephropathy — a condition that can lead to kidney failure.

In this episode, Dr. Pritt and Dr. Morice discuss new developments in monkeypox testing, updates on the federal response, and lessons learned from managing other viruses.

Rong He, M.D., describes how Mayo Clinic Laboratories’ NPM1Q assay detects all known forms of a genetic mutation found in about 30% of people with acute myeloid leukemia, or AML. Identifying the NPM1 mutation is critical for clinical decision-making.

In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Bobbi Pritt, M.D., professor of Laboratory Medicine and Pathology and division chair for the Department of Clinical Microbiology at Mayo Clinic, to discuss why this year’s tick season is more severe than others.

John Osborn, operations administrator in the Department of Laboratory Medicine and Pathology at Mayo Clinic, joins the "Answers From the Lab" podcast for a discussion with host Bobbi Pritt, M.D. about monkeypox testing. In this episode, John and Dr. Pritt discuss how Mayo Clinic swiftly operationalized monkeypox testing and the challenges involved with supporting the new assay, including staffing.

Rajiv Pruthi, M.B.B.S., explains how Mayo Clinic Laboratories’ serotonin release assay achieves high sensitivity and specificity while avoiding the use of radioactive materials. Serotonin release testing is an important tool in the diagnosis of heparin induced thrombocytopenia, or HIT, which can have devastating consequences for patients.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with podcast host Bobbi Pritt, M.D. In this episode, Dr. Pritt and Dr. Morice discuss the World Health Organization’s declaration of monkeypox as a global public health emergency, how Mayo Clinic Laboratories quickly implemented testing, and the public-private partnership to manage the response.

Joshua Bornhorst, Ph.D., describes the new, FDA-approved Alzheimer's disease (AD) test and how it differs from Mayo Clinic Laboratories' existing AD evaluation. The laboratory will offer both tests, to ensure flexibility and options for managing clinical care.

In this episode, Dr. Pritt and Dr. Morice discuss the science behind the increasing COVID-19 infections, why individuals can get reinfected with different variants, and the effectiveness of the at-home antigen tests.

In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Joseph Maleszewski, M.D., professor of Laboratory Medicine and Pathology and consultant in Anatomic Pathology at Mayo Clinic, to discuss the trending topic of 3D imaging technology.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with podcast host Bobbi Pritt, M.D. In this episode, Dr. Pritt and Dr. Morice discuss advances in monkeypox testing, working with the CDC to scale testing and response efforts, the fast-spreading BA.5 variant of COVID-19, and how at-home testing affects the number of reported cases.

In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Darci Block, Ph.D., assistant professor of Laboratory Medicine and Pathology and consultant in Clinical Core Laboratory Services at Mayo Clinic, to discuss challenges of saliva testing.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with podcast host Bobbi Pritt, M.D. In this episode, Dr. Pritt and Dr. Morice discuss the recent Department of Health and Human Services announcement that named Mayo Clinic Laboratories as one of five commercial labs to expand capacity for monkeypox testing. They also discuss newly introduced legislation – the Saving Access to Laboratory Services Act (SALSA).